Document:

EX-10.56

 Exhibit 10.56 

AMENDED AND RESTATED 

RELEASE 
 THIS AMENDED AND
RESTATED RELEASE (this “Agreement”) is made and entered into as of this 28th day of January, 2020, by and among, on the one hand, Mr. Jonathan Jackson, an individual (“Jackson”), Lordship Ventures
LLC, a Delaware limited liability company (“Lordship Ventures”), and Lordship Ventures Histogen Holdings LLC, a Delaware limited liability company (“Lordship Holdings”), and on the other hand, Histogen
Inc., a Delaware corporation (the “Company”). This Agreement refers to Lordship Ventures, Lordship Holdings, and Jackson each as a “Lordship Party” and collectively as the “Lordship
Group”, and to each of the parties named above as a “Party” and together as the “Parties”. 

RECITALS 
 A. The
Company has entered into that certain Agreement and Plan of Merger and Reorganization, dated January 28, 2020, by and among Conatus Pharmaceuticals Inc., a Delaware corporation (the “Parent”), Chinook Merger Sub, Inc., a
Delaware corporation and wholly owned subsidiary of Parent (the “Merger Sub”) and the Company, pursuant to which the Merger Sub shall be merged with and into the Company and the Company will continue as the surviving
corporation (the “Contemplated Transaction”). 
 B. The Company and the Lordship Group, in connection with the
closing of the sale of the Company’s Series D Preferred on August 10, 2016 (the “Financing”), entered into certain Conversion, Termination and Release Agreement (the “Prior Agreement”) dated
August 10, 2016. 
 C. The Parties have met their obligations under several provisions of the Prior Agreement and wish to amend and
restate the Prior Agreement to include only those provisions pursuant to which a Party has a continuing obligation after the Effective Time (as defined herein). 

D. Pursuant to Section 16.6 of the Prior Agreement, any term of the Prior Agreement may be amended, terminated or waived with the written
consent of the Company and a Person in the Lordship Group, and any such amendment, termination or waiver by a Person in the Lordship Group will be binding upon each Person in the Lordship Group and any assignees. 

E. The Company and each Lordship Party wish to amend and restate the Agreement as set forth herein in connection with, and contingent upon, the
closing of the Contemplated Transaction, to be effective immediately prior to the closing of such Contemplated Transaction. 
 NOW,
THEREFORE, in consideration of these premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows: 

1. Definitions. For purposes of this Agreement, in addition to the bold capitalized terms defined in other Sections of this Agreement,
the following terms shall have the meanings ascribed to them below: 
 “Affiliate” means, with respect to any
Person, (a) any other Person who directly or indirectly, controls, is controlled by or is under common control with such Person, including any general partner, limited partner, managing member, officer or director of such Person, or any venture
capital fund now or hereafter existing which is controlled by one or more general partners or managing members of, or shares the same management company with, such Person, or (b) a general or limited partner of such Person. 

  
 -1- 

 “Claim” means any claim, action, cause of action, demand, lawsuit,
arbitration, inquiry, audit, notice of violation, proceeding, litigation, citation, summons, subpoena or investigation of any nature, civil, criminal, administrative, regulatory or otherwise, whether at law or in equity. 

“Continuing Agreements” means those agreements between the Company and any Lordship Party set forth under the heading
“Continuing Agreements” on Schedule A. 
 “Effective Time” means immediately before the closing of
the Financing. 
 “Financing Closing” means the closing of the Financing that occurred on August 10, 2016. 

“Governmental Body” means any: (A) nation, state, county, city, town, district, or other jurisdiction of any
nature; (B) federal, state, local, municipal, foreign, or other government; (C) governmental or quasi-governmental authority of any nature (including any governmental agency, branch, department, official, or entity and any court or other
tribunal); (D) multinational organization or body; or (E) body exercising, or entitled to exercise, any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power of any nature. 

“Lordship Agreement” means each agreement entered into by the Company and any Lordship Party prior to the Effective
Time (excluding the Continuing Agreements), and collectively the “Lordship Agreements”. 
 “Lordship
Protective Rights” means any and all rights of first refusal, rights of participation, rights of notice, pre-emptive rights, anti-dilution rights and/or any other rights, privileges, or claims any
Lordship Party may have or have had under any Lordship Agreement or Continuing Agreement. 
 “Loss” means any
liability, loss, claim, settlement payment, cost, expense, interest, award, judgment, damages (including punitive damages), diminution in value, fines, fees, penalties or other charge, and any taxes. 

“Person” means any individual, corporation, general or limited partnership, limited liability company, joint venture,
trust, association, organization, or other entity or Governmental Body. 
 “Previous Stockholder Agreements” means
those agreements set forth under the heading “Previous Stockholder Rights Agreements” on Schedule A. 

“Previous Stockholder Rights” means any rights of the Lordship Parties, obligations of the Company or restrictions on
the Company that were intended to (or did) protect the Lordship Parties or its rights as a stockholder under the Previous Stockholder Agreements, all previous Certificates of Incorporation (the Fourth Amended and Restated Certificate of
Incorporation, the Third Amended and Restated Certificate of Incorporation, the Second Amended and Restated Certificate of Incorporation, the (previous) Amended and Restated Certificate of Incorporation and the original Certificate of Incorporation)
and previous Bylaws of the Company. 
 “Released Parties” means Company, its Affiliates, and each of their
respective current and former officers, directors, employees, members, agents, investors, attorneys, shareholders, administrators, insurers, representatives, trustees, divisions, and subsidiaries, and predecessor and successor Persons and assigns.

  
 -2- 

 2. Release of Claims. 

2.1 Lordship. 
 2.1.1
Lordship Group Primary Release. In consideration for entering into this Agreement and other consideration that each Lordship Party hereby acknowledges as sufficient, Lordship Ventures, Lordship Holdings and Jackson, on its own behalf and on
behalf of each of its or his Affiliates, and each of its or his respective officers, directors, members, managers, partners, representatives, agents, heirs, family members, executors, agents, and assigns (collectively, “Lordship
Releasors”), hereby and forever irrevocably releases the Released Parties from, and agrees not to sue concerning, or in any manner to institute, prosecute, or pursue, any Claim, complaint, charge, duty, obligation, demand, or cause of
action relating to any matters of any kind, and waives and discharges each of the foregoing, whether presently known or unknown, suspected or unsuspected, accrued or unaccrued, contingent or otherwise, that any of the Lordship Releasors may possess
against any Released Party arising from any omissions, acts, facts, damages or Losses, that have occurred up until, and including, the Financing Closing, including, as pertaining to any Lordship Agreement, the Previous Stockholder Rights, any
Lordship Protective Right or the Financing, provided, however, that nothing in this Section 2.1.1 applies, in any way to anything related to the Lordship Releasor’s rights under or with respect to the
Continuing Agreements. Each Person in the Lordship Group represents and warrants that, as of the Effective Time, such Person has made no assignment or transfer of any right, claim, complaint, charge, duty, obligation, demand, cause of action, or
other matter waived or released by this Section 2.1.1. 
 2.1.2 Lordship Group Specific Release. In
consideration for entering into this Agreement and other consideration that each Lordship Party hereby acknowledges as sufficient, Lordship Releasors, hereby and forever irrevocably releases the Released Parties from, and agrees not to sue
concerning, or in any manner to institute, prosecute, or pursue, any Claim, complaint, charge, duty, obligation, demand, or cause of action, and waives and discharges each of the foregoing, whether presently known or unknown, suspected or
unsuspected, accrued or unaccrued, contingent or otherwise, that any of the Lordship Releasors may possess against any Released Party arising from any breach by the Company of its representations, warranties, covenants or other obligations under the
Continuing Agreements that have occurred any time up until, and including, the Financing Closing. Each Person in the Lordship Group represents and warrants that, as of the Effective Time, such Person has made no assignment or transfer of any right,
claim, complaint, charge, duty, obligation, demand, cause of action, or other matter waived or released by this Section 2. 

2.2 Company. In consideration for entering into this Agreement and other consideration that the Company hereby acknowledges as
sufficient, the Company on its own behalf and on behalf of each of its Affiliates, and its respective officers, directors, members, managers, partners, representatives, agents, heirs, family members, executors, agents, and assigns (collectively,
“Company Releasors”), hereby and forever irrevocably releases Lordship Ventures, Lordship Holdings and Jackson and each of their respective Affiliates, and each of their respective current and former officers, directors,
employees, agents, investors, attorneys, members, shareholders, administrators, insurers, representatives, trustees, divisions, and subsidiaries, and predecessor and successor Persons and assigns (collectively, the “Lordship Released
Parties”) from, and agrees not to sue concerning, or in any manner to institute, prosecute, or pursue, any Claim, complaint, charge, duty, obligation, demand, or cause of action relating to any matters of any kind, and waives and
discharges each of the foregoing, whether presently known or unknown, suspected or unsuspected, accrued or unaccrued, contingent or otherwise, that Company Releasors may possess against any Lordship Released Party arising from any omissions, acts,
facts, damages or Losses, that have occurred up until, and including, the Financing Closing, including, as pertaining to any Lordship Agreement, any Lordship Protective Right or the Financing. The Company represents and warrants that, as of the
Effective Time, the Company has made no assignment or transfer of any right, claim, complaint, charge, duty, obligation, demand, cause of action, or other matter waived or released by this Section 2. 

  
 -3- 

 2.3 Scope. To clarify the intent of the Parties, nothing in this
Section 2 will be read to waive breaches or defaults after the Financing Closing by any of the Parties under the Continuing Agreements, or to release any Claims or Losses arising after the Financing Closing. The release and
agreements not to sue under this Section 2 do not extend to the obligations, representations or warranties under this Agreement. 

3. California Civil Code Section 1542. The Company and the Lordship Parties acknowledge that they have been advised
to consult with legal counsel and are familiar with the provisions of California Civil Code Section 1542, a statute that otherwise prohibits the release of unknown claims, which provides as follows: 

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE
TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY. 

The Company and the Lordship Parties, being aware of said code section, agree that each release set forth in Section 2 is intended
as a full and complete release, and agree to expressly waive any rights they may have thereunder, as well as under any other federal or state statute or common law principles of similar effect. 

4. No Pending or Future Lawsuits. Each Lordship Party represents and warrants that such Party has no lawsuits, claims, or actions
pending in such Party’s name, or on behalf of any other Person or entity, against any Released Party. Each Lordship Party also represents and warrants that such Party does not intend to bring any claims on such Party’s own behalf or on
behalf of any Released Party. The Company represents and warrants that it has no lawsuits, claims, or actions pending in its name, or on behalf of any other Person or entity, against any Lordship Released Party. The Company also represents and
warrants that it does not intend to bring any claims on their own behalf or on behalf of any Released Party. 
 5. Third Party
Beneficiaries. The Released Parties (other than Company) are third party beneficiaries of this Agreement in accordance with its terms. The Lordship Released Parties (other than the Lordship Parties) are third party beneficiaries of this
Agreement in accordance with its terms. 
 6. Lordship Group Additional Waiver. Each Lordship Party hereby unconditionally and
irrevocably waives any and all Lordship Protective Rights in connection with the Contemplated Transaction. 
 7. Miscellaneous. 

7.1 Successors and Assigns. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective
successors and assigns of the Parties. Nothing in this Agreement, express or implied, is intended to confer upon any Person other than the Parties or their respective successors and assigns any rights, remedies, obligations, or liabilities under or
by reason of this Agreement, except as expressly provided in this Agreement. 
 7.2 Governing Law. This Agreement shall be governed
by, and construed in accordance with, the laws of the State of Delaware, without regard to conflict of law principles that would result in the application of any law other than the law of the State of Delaware. 

7.3 Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including .pdf) or other transmission method and any counterpart so delivered shall be deemed to have been duly and
validly delivered and be valid and effective for all purposes. 

  
 -4- 

 7.4 Titles and Subtitles. The titles and subtitles used in this Agreement are used
for convenience only and are not to be considered in construing or interpreting this Agreement. 
 7.5 Notices. All written notices
hereunder by any Party shall be given by personal delivery (including reputable courier service), fees prepaid, or by sending such notice by registered or certified mail return receipt requested, postage prepaid or via an internationally recognized
overnight courier service. Such notices shall be deemed to have been given, delivered and received upon receipt or attempted delivery (if receipt is refused), as the case may be, and the date of delivery identified by the applicable postal service
on any return receipt card or confirmation by courier service, even if such delivery was refused. Notices also may be sent by facsimile transmission or email, which shall be deemed given, delivered and received when sent if: (a) the Party
transmitting the notice also sends such notice the same day by any of the other notice methods described above; or (b) the receiving Party confirms receipt in any manner. Each such notice must name the individual and title designated for
notices and be addressed to the Party as set forth on the signature pages below. Any Party, by five (5) days written notice to the other as above described, may alter the address or named recipient for receipt by it of written notices
hereunder. If notice is given to the Lordship Group, a copy shall also be sent to Satz Law Group LLC, 230 Passaic Avenue, 1st floor, Fairfield, NJ 07004, Attn: Brian M. Satz, Esq., Facsimile: (973) 255-1010,
Email: bsatz@satzlawgroup.com; and if notice is given to the Company, a copy shall also be given to Sheppard, Mullin, Richter & Hampton LLP, 333 S. Hope Street, 48th Floor, Los Angeles, CA 90071, Attn: Will Sarat Chuchawat, Esq., Facsimile:
(213) 443-2708, Email: wchuchawat@sheppardmullin.com. 
 7.6 Amendments and Waivers. Any term
of this Agreement may be amended, terminated or waived only with the written consent of the Company and a Person in the Lordship Group. Any amendment, termination or waiver by a Person in the Lordship Group will be binding upon each Person in the
Lordship Group and any assignees. 
 7.7 Further Assurances. Each of the Parties hereto shall, at its expense, and shall cause its
respective Affiliates to, from time to time at the request of the other Party, without any additional consideration, furnish the other Party such further information or assurances, execute and deliver such additional documents, instruments and
conveyances, and take such other actions and do such other things, as may be reasonably necessary, appropriate or desirable, to carry out the provisions of this Agreement and give effect to the transactions contemplated hereby. 

7.8 Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to any party under this Agreement, upon
any breach or default of any other party under this Agreement, shall impair any such right, power or remedy of such non-breaching or non-defaulting party nor shall it be
construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or
default previously or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or
conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not
alternative. 
 7.9 Severability. If any provision of this Agreement is held invalid or unenforceable by an arbitrator in arbitration
or by a court of competent jurisdiction, the court or arbitrator should endeavor to give effect to the Parties’ intentions as reflected in such provision, and if the court or arbitrator cannot do so, then strike the invalid or unenforceable
provision in which case this entire Agreement will be construed as if not containing such particular invalid or unenforceable provision and the rights and obligations of the Parties will be construed and enforced accordingly with the remaining
provisions given their full force and effect. 

  
 -5- 

 7.10 Entire Agreement. This Agreement (including the Exhibits hereto) constitutes the
full and entire understanding and agreement between the Parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the Parties is expressly canceled. The terms
and conditions of this Agreement amend and modify any conflicting terms and conditions of any Continuing Agreement (or any other agreement between the parties as of the Financing Closing). 

7.11 Dispute Resolution. Any dispute, controversy or claim arising from this Agreement other than for injunctive or other equitable
relief, shall be submitted to final, binding and non-appealable arbitration before the American Arbitration Association (the “AAA”). A single neutral arbitrator shall preside unless a
Party requests a panel of three neutral arbitrators, in which case three arbitrators will preside, and the Party that requested a proceeding with three arbitrators will pay 2/3 of the fees of the arbitrators presiding. To the extent the identity of
the arbitrator(s) is not agreed by the Parties within fourteen (14) days following the commencement of notice by any Party of its intention in writing to immediately submit a dispute for arbitration, the AAA will have the discretion to select
the neutral arbitrator that it believes is best suited for the arbitration in terms of experience and availability, having reasonable experience in corporate finance transactions of the type provided for in this Agreement, and its selection will be
final. Such arbitration shall take place in Los Angeles, California, and shall be conducted in accordance with the commercial rules of the AAA then in effect. Any matters (such as petitions for injunctions or other equitable relief) not otherwise
covered by the aforementioned arbitration by the AAA shall be resolved exclusively in the state and federal courts located in the City of Los Angeles, California, and each Party irrevocably and unconditionally (a) submits to the exclusive
jurisdiction and venue of the United States District Court for the Central District of California, or any state court sitting in Los Angeles County, California, for the purpose of any suit, action or other proceeding arising out of or based upon
this Agreement, (b) hereby waives, and agrees not to assert any claim that it is not subject personally to the jurisdiction of the above-named courts, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of
the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court. 

7.12 Interpretation. This Agreement does not create a partnership, franchise, joint venture, agency, fiduciary or employment
relationship between the Parties. The word “or” as used in this Agreement has the meaning equivalent to “and/or”. The terms ‘include’ and ‘including’ will be deemed to be immediately followed by the phrase
“without limitation”. This Agreement does not confer any rights or benefits to any third party beneficiaries except for as stated in Section 2. The headings appearing at the beginning of sections have been
inserted for identification and reference purposes only and must not be used to construe or interpret this Agreement. The word “will” expresses an obligation of a party equivalent to “shall” when a party is the subject of the
sentence. The Agreement will not be construed in favor of or against any party by reason of the extent to which any party participated in the preparation of this Agreement. The headings appearing at the beginning of several Sections contained in
this Agreement have been inserted for identification and reference purposes only and must not be used to construe or interpret this Agreement. Should any terms of this Agreement be determined to be otherwise void or unenforceable by any arbitrator
or court of competent jurisdiction, such terms will be deemed amended to achieve as nearly as possible the same economic effect as the original terms and the remainder of this Agreement will remain in full force and effect. The parties hereto
confirm that they have requested that this Agreement and all attachments and related documents be drafted in English. 
 [Signature Page
Follows] 

  
 -6- 

 IN WITNESS WHEREOF, the Parties have executed this Amended and Restated Release as of the
date first above written. 
  

	
	COMPANY
	
	 Histogen Inc.
 10655 Sorrento Valley
Road

	San Diego, CA 92121
	Attention: Chief Executive Officer
	Facsimile:
	Email:
	
	 /s/ Richard W. Pascoe

	By Richard W. Pascoe, Chief Executive Officer

 Signature Page to Amended and Restated Release 

 IN WITNESS WHEREOF, the Parties have executed this Amended and Restated Release as of the
date first above written. 
  

	
	LORDSHIP VENTURES LLC
	c/o Lordship A.S.
	
	Attention: Jonathan Jackson
	Facsimile:
	Email:
	
	 /s/ Jonathan Jackson

	By Jonathan Jackson, Managing Member
	
	LORDSHIP VENTURES HISTOGEN HOLDINGS LLC
	c/o Lordship A.S.
	
	Attention: Jonathan Jackson
	Facsimile:
	Email:
	
	 /s/ Jonathan Jackson

	By Jonathan Jackson, Managing Member
	
	JONATHAN JACKSON
	c/o Lordship A.S.
	
	Attention: Jonathan Jackson
	Facsimile:
	Email:
	
	 /s/ Jonathan Jackson

	By Jonathan Jackson

 Signature Page to Amended and Restated Release 

 Schedule A 

Lordship Agreements 
 Continuing
Agreements 
 Amended and Restated Strategic Relationship Success Fee Agreement, dated August 10, 2016, by and between Histogen Inc., a Delaware
corporation (“Company”) and Lordship Ventures LLC, a Delaware limited liability company (“Lordship Ventures”). 

Release, dated as of October 5, 2013, by and between Company and Lordship Ventures. 

Indemnification Agreement, dated as of January 12, 2012, by and between Company and Lordship Ventures. 

Previous Stockholder Rights Agreements 
 Right of First
Refusal and Co-Sale Agreement, dated November 19, 2012, by and among Company, Lordship Ventures Histogen Holdings LLC, a Delaware limited liability company (“Lordship Holdings”),
and certain stockholders of the Company. 
 Voting Agreement, dated November 19, 2012, by and among the Company, Lordship Holdings, and certain
stockholders of the Company. 
 Investor Rights Agreement, dated November 19, 2012, by and between Company and Lordship Holdings. 

Schedule A to Amended and Restated ReleaseEX-10.58

 Exhibit 10.58 

 

					
	

	  		  	 Canaccord Genuity LLC

99 High Street
 Suite 1200

Boston, MA
 USA 02110

 
 T1: 1.617.371.3900

T2: 1.800.225.6201

cgf.com

 CONFIDENTIAL 

November 8, 2019 
 Histogen, Inc. 

10655 Sorrento Valley Road 
 San Diego, CA 92121 

Attention: Richard Pascoe 

       Chairman and Chief Executive Officer 

Dear Richard: 
 This letter agreement (including Annex A
hereto, this “Agreement”) will confirm our understanding of the terms and conditions under which Canaccord Genuity LLC (“Canaccord Genuity”) is engaged by Histogen, Inc., a Delaware corporation and any
subsidiary thereof (collectively, the “Company”) as its exclusive financial advisor with respect to consummating (a) one or several possible business combinations, whether in one or a series of related transactions, through the
purchase of an organization’s equity or by means of a merger, consolidation, reorganization, joint venture, reverse merger, partnership, tender offer, exchange offer, strategic alliance, or any other transaction of a like nature, regardless of
form, with a Public Company (as defined below) which results in the Company (or its successor or the acquiror of a majority of its assets) being a Public Company (a “Reverse Merger”), and (b) one or more private placements or
public offerings of Instruments (as defined below) (I) of the Company occurring concurrently with a Reverse Merger, or (II) of any successor to the Company occurring concurrently with or following a Reverse Merger (the immediately
foregoing clauses (I) and (II) collectively, a “Financing”). For the sake of clarity, (A) private placements of Instruments of the Company that occur prior to and not in connection with a Reverse Merger shall not be deemed
a Financing, and (B) any private placement or public offering of Instruments related to a Reverse Merger, directly or indirectly, shall be deemed a Financing hereunder. For the avoidance of doubt, if a Financing is executed in more than one
issuance or tranche which form part of the same financing plan, then all such issuances and tranches shall collectively be deemed a single Financing for the purposes of this Agreement. 

Notwithstanding anything to the contrary herein, a Financing shall not include the sale, assignment or other transfer of outstanding securities by an
equityholder of the Company (i) for estate planning purposes, (ii) in a divorce, bankruptcy or similar circumstances, (iii) to its partners, members or other equityholders, or (iv) to the Company, another equityholder of the
Company, an Affiliate (as defined below), a Family Member (as defined below) or an Affiliate of a Family Member or another equityholder of the Company. 

It is understood and agreed that the Company’s engagement of Canaccord Genuity pursuant to this Agreement is not an express or implied commitment by, nor
shall this Agreement otherwise create any obligation on, Canaccord Genuity to underwrite, place, or purchase any Instruments or otherwise provide or arrange any financing. 

 Histogen, Inc. 

November 8, 2019 
  Page
 2
 of 15 
  

 “Instruments” shall mean common stock, preferred stock, or other equity securities
(individually and collectively, “Equity Securities”). “Public Company” means an entity that has a class of securities registered under Section 12 or subject to Section 15(d) of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”). “Affiliate” means, with respect to any Person (as defined below), any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled
by, or is under common control with such first Person. “Family Member” means, with respect to any individual, the lineal ascendants, lineal descendants, and siblings, whether related by blood or by adoption, of such individual or
such individual’s spouse or domestic partner, and such individual’s spouse or domestic partner. “Person” means any corporation, limited liability company, partnership, trust or other entity or an individual. 

1. Services. The Company hereby engages Canaccord Genuity to act as its exclusive financial advisor and participate and assist in negotiations with
respect to exploring, negotiating and consummating a Reverse Merger and a Financing (collectively, the “Transactions”) during the Term (as defined below), and Canaccord Genuity hereby accepts such engagement. As financial advisor,
Canaccord Genuity shall perform such financial advisory and investment banking services as the Company may reasonably request in connection with a potential Transaction, including: 

(a) analyzing and evaluating the business, operations, financial condition and prospects of the Company; 

(b) reviewing with members of management the Company’s financial plans and analyze its strategic plans and business alternatives; 

(c) being available at the Company’s request to meet with its Board of Directors to discuss strategic alternatives and their financial
implications; 
 (d) collaborating with the Company to develop and execute a strategy for completing a Reverse Merger and Financing and the
appropriate structure, terms and conditions thereof; 
 (e) in consultation with the Company, play the lead role in identifying, qualifying
and contacting potential investors in a Financing (the “Investors”) and in soliciting, coordinating and evaluating indications of interest and proposals regarding the Transactions; provided that Canaccord Genuity shall not
contact any Investor or potential counterparty to a Reverse Merger (a “Counterparty”), or introduce any such Counterparty to the Company, until such Person has been approved by the Company in writing; 

(f) preparing offering materials detailing the Transactions for distribution and presentation to Investors (collectively, “Marketing
Materials”); provided, however, that the Company must approve all Marketing Materials and any distribution thereof in writing prior to their use); 

(g) updating the Company on a regular basis regarding the process and any substantive communications with any Investors or Counterparties,
including the dates and nature thereof; 

 Histogen, Inc. 

November 8, 2019 
  Page
 3
 of 15 
  

 (h) evaluating and comparing Transaction proposals made to the Company; 

(i) coordinating and attending meetings (including due diligence meetings) with Investors, Counterparties and the Company; 

(j) responding to inquiries by Investors or Counterparties; 

(k) advising the Company in its negotiations regarding the Transactions, including, as required, negotiating (along with Company legal counsel)
definitive agreements; 
 (l) coordinating with the Company’s legal counsel regarding matters related to the closing of a Transaction;
and 
 (m) providing such other financial advisory and investment banking services reasonably necessary to accomplish the foregoing,
including financial and strategic analysis necessary to facilitate the proper and timely integration of the financial, tax, and merger and acquisition aspects of the Transactions. 

2. Information. The Company will furnish and, if applicable, will request any third party to furnish Canaccord Genuity such information as Canaccord
Genuity reasonably requests in connection with the performance of its services hereunder (all such information so furnished is referred to herein as the “Information”). The Company agrees that Canaccord Genuity, in performing its
services hereunder, will use and rely upon the Information without assuming any responsibility for independent investigation or verification thereof. Accordingly, Canaccord Genuity shall be entitled to assume and rely upon the accuracy and
completeness of all such Information. Canaccord Genuity will assume that any forecasts and projections have been prepared in good faith and reflect reasonable estimates and judgments of the management of the Company, the relevant target or strategic
partner, as the case may be, as to the matters covered thereby. 
 3. Confidentiality. 

(a) Canaccord Genuity shall keep confidential all information (the “Confidential Information”) provided by the Company or its
employees, officers, directors, equityholders, affiliates, attorneys, accountants, consultants, advisors and other representatives (collectively, “Representatives”) to Canaccord Genuity or its Representatives. Canaccord Genuity
shall not use, and cause its Representatives not to use, any Confidential Information except for the benefit of the Company in connection with performing the services to the Company pursuant to the engagement, and shall not disclose, and cause its
Representatives not to disclose, any Confidential Information to any Person except (a) with the Company’s prior written consent, (b) a Counterparty or Investor who has executed and delivered a confidentiality agreement, in form
approved in writing by the Company, to the Company, (c) those of its Representatives who need access to any Confidential Information for purposes of performing the services to be provided by Canaccord Genuity hereunder, provided that each such
Representative is bound by a duty or obligation of confidentiality to Canaccord Genuity and has been advised of the confidentiality thereof; it being understood that Canaccord Genuity shall 

 Histogen, Inc. 

November 8, 2019 
  Page
 4
 of 15 
  

 
be liable for any unauthorized use or disclosure by any such Representative, or (d) as may be required by legal process or regulatory authority; provided that in the event that
Canaccord Genuity or any of its Representatives are requested or required by law, regulatory authority or other applicable judicial or governmental order to disclose any Confidential Information, and such request, requirement, or order specifically
references the Company, Canaccord Genuity or such Representative shall, if permitted by applicable law, provide the Company with notice of any such request, requirement, or order as promptly as reasonably practicable so that the Company may seek a
protective order or other appropriate remedy (at the Company’s sole expense) or waive compliance with the terms of this Agreement; provided, further, that in the event that such protective order or other remedy is not obtained for
any reason, or that the Company waives compliance with the terms hereof, Canaccord Genuity or its Representatives, as applicable, may disclose that portion of the Confidential Information which Canaccord Genuity or its Representatives, as the case
may be, believes in good faith, on advice on counsel, is legally required to be disclosed, but will use its reasonable efforts to obtain reliable assurance that confidential treatment will be accorded the Confidential Information. 

(b) The term “Confidential Information” includes the financial terms of this Agreement, the fact that Transactions are potentially
taking place and the terms, conditions and status thereof, but does not include information which: (i) was already in Canaccord Genuity’s possession prior to the time of disclosure to it by the Company or any of its Representatives without
being subject to any obligation or duty of confidentiality or non-disclosure, (ii) was or becomes generally available to the public other than as a result of a disclosure by Canaccord Genuity or any of
its Representatives, (iii) becomes available to Canaccord Genuity on a non-confidential basis from a source other than the Company or any of its Representatives, provided that such source is not bound by any
obligation of duty of confidentiality or non-disclosure with respect to such information, or (iv) which was or is independently developed or discovered by Canaccord Genuity without the use of any
Confidential Information. 
 (c) Canaccord Genuity and its Representatives shall keep (and Canaccord Genuity shall cause its Representatives
to keep) the Confidential Information confidential by using the same degree of care as Canaccord Genuity uses with its own confidential or proprietary information of a similar nature, but not less than a reasonable degree of care. 

(d) Upon the Company’s written request, Canaccord Genuity and its Representatives shall at its option either promptly destroy or delete
(and Canaccord Genuity shall cause its Representatives promptly to destroy or delete) all Confidential Information in written, stored or any other tangible form, and any copies thereof; provided, however, that Canaccord Genuity and its
Representatives may retain copies of Confidential Information, subject to all of the other terms of this Section 3 (which shall survive any termination hereof with respect to all such retained copies), in accordance with their respective
internal record retention policies for legal, compliance or regulatory purposes or to establish the rights of Canaccord Genuity and its Representatives under this Agreement. 

 Histogen, Inc. 

November 8, 2019 
  Page
 5
 of 15 
  

 (e) Canaccord Genuity and its Representatives agree and acknowledge that as between Canaccord
Genuity or its Representatives and the Company, the Confidential Information is and shall remain the sole and exclusive property of the Company, and that no license or similar proprietary right is granted to Canaccord Genuity or its Representatives
or any other Person hereunder. 
 (f) Canaccord Genuity and its Representatives acknowledge that remedies at law would be inadequate to
protect the Company against any actual or threatened breach of this Section 3 by Canaccord Genuity or its Representatives, and, without prejudice to any other rights and remedies otherwise available to the Company, Canaccord Genuity and
its Representatives agree to the granting of injunctive relief in favor of the Company without proof of actual damages, proving the inadequacy of money damages, proving the likelihood of success, or (to the extent permitted by law) without posting a
bond or other security. 
 4. Marketing. It is expected that the Instruments will be offered and sold on a private placement basis as agreed upon by
the Company and Canaccord Genuity in the United States and Canada (the “Qualifying Jurisdictions”) by way of private placement to selected accredited investors and/or to qualified institutional buyers and outside of the United
States and Canada on a private placement or equivalent basis in accordance with applicable laws, as is mutually agreed between the Company and Canaccord Genuity. 

The Company shall cause appropriate senior personnel to make themselves available to participate in the marketing of the Financing, including assisting in the
preparation of Marketing Materials and attending roadshows and other investor meetings. All orders and expressions of interest in Transactions shall be referred to Canaccord Genuity. 

The Company authorizes Canaccord Genuity to distribute Marketing Materials to prospective Investors in a Financing or potential Counterparties in a Reverse
Merger; provided that Canaccord Genuity shall not (a) distribute or disclose any Marketing Materials or any other Confidential Information to any Person that has not been approved by the Company in writing, or (b) provide any
material non-public information regarding any Public Company which may be involved in a Reverse Merger, including the identity of such Public Company, to any Person without an express agreement by such Person
(whether oral or written) not to disclose, or trade on the basis of, that information. Marketing Materials, together with any reports, statements and other documents publicly filed by the Company with regulatory agencies (collectively, the
“Materials”) shall be the subject of Canaccord Genuity’s review and approval prior to distribution (such approval not to be unreasonably withheld, delayed or conditioned). 

The Company acknowledges that the Company shall be solely responsible for the accuracy and completeness of the Materials and all other information distributed
in connection with a Financing, and agrees that such Materials and information shall not contain any untrue statement of material fact, or omit to state a material fact necessary to make the statements contained therein, in light of the
circumstances in which they were made, not misleading. If, prior to the pricing of a Financing, any event shall occur or condition shall exist as a result of which it is necessary to amend or 

 Histogen, Inc. 

November 8, 2019 
  Page
 6
 of 15 
  

 supplement the Materials in order to cause the statements therein not to omit to state a material fact
necessary in order to make the statements made therein, in the light of the circumstances in which they are made, not misleading, the Company shall promptly prepare and furnish to Canaccord Genuity such amendments or supplements. The Company shall
comply, and shall assist Canaccord Genuity in complying, with all federal, state, and provincial securities laws and regulations applicable to the Financing; provided that Canaccord Genuity shall not engage in any general solicitation or make
any general advertisement in any jurisdiction without the prior written consent of the Company. 
 The Company agrees that (i) at the closing of the
Financing, it shall cause its outside counsel to issue to Canaccord Genuity an opinion reasonably acceptable to Canaccord Genuity to the effect that any sale of the Instruments was exempt from the registration requirements of the Securities Act of
1933, as amended, and (ii) Canaccord Genuity will be entitled to rely, as an express third-party beneficiary, on the representations, warranties and covenants of the Company and the investors in such Financing that are set forth in the
definitive agreement between the Company and the investors in such Financing (such agreement or agreements, collectively, the “Purchase Agreement”). 

5. Fees. In consideration for its services hereunder, the Company shall pay Canaccord Genuity, by wire transfer of immediately available funds in lawful
money of the United States to such accounts at commercial banks in the United States as Canaccord Genuity shall identify upon written notice to the Company at the time due, the following fees: 

(a) upon signing of this Agreement, a non-refundable retainer fee of $25,000, and an additional $25,000
on the month anniversary of such date (notwithstanding any earlier termination of the Agreement by the Company) (collectively, the “Retainer Fee”) and any such Retainer fee actually paid by the Company to Canaccord Genuity shall be
credited against the first Success Fee or Financing Fee (as such terms are defined below) paid by the Company; 
 (b) upon the Closing (as
defined below) of a Reverse Merger, $750,000 (the “Success Fee”); and 
 (c) upon the Closing of a Financing, a fee (the
“Financing Fee”) equal to 7.0% of the gross proceeds of the Investment (as defined below) from sales of Equity Securities; provided, however that under no circumstances will the Financing Fee be less than $500,000. 

(d) For purposes of this Agreement: 

(i) “Closing” shall refer to that date at which the final legal transfer of ownership, as set forth in the
executed definitive asset purchase, stock purchase, merger agreement or similar definitive agreement associated with the Reverse Merger or Financing (the “Definitive Agreement”) occurs. 

 Histogen, Inc. 

November 8, 2019 
  Page
 7
 of 15 
  

 (ii) “Investment” shall include the gross dollar amount
delivered or committed to be delivered to the Company in the form of cash or other such funding, including sales of existing Company Equity Securities. For purposes of calculating the gross dollar amount, (A) any currency other than United States
dollars shall be translated into United States dollars at the rate of exchange published in The Wall Street Journal on the Closing date thereof or at the prevailing market rate on such date if no such rate is published, and (B) only fifty
percent (50%) of the proceeds received by the Company from sales to Lordship Ventures or to any of its Affiliates or any funds managed by it or its Affiliates shall be included. 

(e) If, in connection with a Transaction that is not completed, the Company receives a break-up fee,
topping fee or other termination fee (collectively, a “Termination Fee”), the Company will pay Canaccord Genuity a fee equal to 25% of such Termination Fee at the time such Termination Fee is received by the Company. 

6. Expenses. In addition to any fees that may be payable to Canaccord Genuity hereunder and regardless of whether any Transaction is proposed or closed,
the Company hereby agrees to reimburse Canaccord Genuity for all of its reasonable, documented, out-of-pocket expenses arising out of the engagement hereunder, including
travel and related expenses (limited to the cost of commercial economy class for flights under four hours or commercial business class for longer flights), the costs of document preparation, production and distribution (such as printing and binding,
and photocopies, and third party research and database services, and the reasonable fees and disbursements of independent counsel retained by Canaccord Genuity); provided, however, that (a) no expenses relating to the preparation,
negotiation, amendment, or interpretation of this Agreement shall be reimbursable; and (b) any individual expense in excess of $5,000, or aggregate expenses in excess of $60,000, must be pre-approved by
the Company in writing (such approval not to be unreasonably withheld, conditioned or delayed). Canaccord Genuity expects to bill such expenses periodically with payment due within 30 days after a statement therefor with supporting documentation.

 7. Indemnification. In consideration of and as a condition precedent to Canaccord Genuity undertaking the engagement contemplated by this letter,
the Company agrees to the indemnification provisions and other matters set forth in Annex A, which is incorporated by reference into this Agreement. 

8. Due Diligence. It is understood that Canaccord Genuity’ role in any Financing will be subject to the satisfactory completion of investigation
and inquiry into the affairs of the Company as Canaccord Genuity deems appropriate and necessary under the circumstances (“Due Diligence”) and the approval of Canaccord Genuity’ internal committee. Canaccord Genuity shall have
the right, in its sole discretion, to terminate its involvement in a Financing if the outcome of the Due Diligence is not to its satisfaction or if approval of its internal committee is not obtained. 

9. Exclusivity. During the Term, the Company will not, and will not permit its Representatives, to (i) enter into any arrangement or agreement with
any other financial advisor with respect to a Financing or Transaction, or (ii) contact or solicit institutions, corporations or other entities as Investors or Counterparties. Furthermore, the Company agrees that during the Term, all inquiries,
whether direct or indirect, from Investors or Counterparties will be referred to Canaccord Genuity. 

 Histogen, Inc. 

November 8, 2019 
  Page
 8
 of 15 
  

 10. No Obligation to Enter Into a Transaction. The Company shall not be obligated to sell securities
or to accept any offer thereof, or enter into any Transaction, and the terms of any Transaction and the final decision to issue Instruments or enter into a Transaction, shall be subject to the absolute discretionary approval of the Company,
including the right to postpone, modify, abandon, reject or terminate any or all Transactions or to terminate negotiations or due diligence with respect to any Transaction at any time. Canaccord Genuity further acknowledges and agrees that it has no
authority to bind the Company in connection with any Transaction or otherwise. 
 11. Termination of Engagement. The engagement of Canaccord Genuity
hereunder shall become effective upon the date hereof and shall continue until the earliest to occur of (a) either party terminating this Agreement at any time for any reason, upon 10 days’ prior written notice to the other party, and (b)
Canaccord Genuity’s decision to terminate its involvement as set forth in Section 8 (such period, the “Term”). Upon any termination or expiration of the engagement, Canaccord Genuity will be entitled to its full fee
under Section 5 in the event that (i) during the Tail Period (as defined below) a Transaction is consummated with a CG Party (as defined below); or (ii) the Company enters into a definitive agreement during the Term to consummate a
Transaction and such Transaction is ultimately consummated; provided, however, that, at the request of the Company, Canaccord Genuity shall provide advisory services of the type contemplated by this Agreement in connection with such
Transaction at no additional cost to the Company (other than expenses incurred by Canaccord Genuity in accordance with Section 6) notwithstanding the prior termination hereof and as a condition to being paid such Success Fee or Financing Fee.
“Tail Period” means the period commencing at the termination of the Term and ending upon the date 12 months after the termination of the Term. “CG Party” means any Person (i) contacted or introduced to the Company
by Canaccord Genuity during the term of this Agreement in connection with a Transaction, and who affirmatively requested additional information about the Transaction, (ii) who contacted the Company during the term of this Agreement in connection
with a Transaction, (iii) who Canaccord Genuity sought to approach in connection with a Transaction, but was prevented from doing so by the Company, or (iv) with respect to whom Canaccord Genuity or the Company had substantive discussions regarding
a Transaction during the term of this Agreement. The terms and provisions of this Section 11 and of Sections 3, 6, 7, 8, 10, and 12 - 16 and Annex A shall survive the termination
of the Term and the Tail Period. 
 12. Reliance on Others. Canaccord Genuity does not provide accounting, tax or legal advice. The Company confirms
that it will rely on its own independent counsel and independent accountants for such advice. 
 13. No Rights in Shareholders, etc. Canaccord Genuity
has been engaged only by the Company, and this engagement of Canaccord Genuity is not intended to confer rights upon any shareholder, partner or other owner of the Company or any other Person not a party hereto. Unless otherwise expressly agreed, no
one other than the Company is authorized to rely on any statements, advice, 

 Histogen, Inc. 

November 8, 2019 
  Page
 9
 of 15 
  

 
opinions or conduct by Canaccord Genuity. Any opinions or advice rendered by Canaccord Genuity to the Company’s Board or management in the course of this engagement are for the purpose of
assisting the Company’s Board or management, as the case may be, in evaluating the Transactions contemplated hereby and such opinions or advice do not constitute a recommendation to any shareholder of the Company concerning action that such
shareholder might or should take in connection with a Transaction. Canaccord Genuity’s role herein is that of an independent contractor and nothing contained herein is intended to create or shall be construed as creating a fiduciary
relationship between Canaccord Genuity and the Company or its security holders, employees or creditors. 
 14. Other Activities. Canaccord Genuity is
a full-service securities firm engaged, either directly or through its affiliates, in various activities, including securities trading, investment management, financing and brokerage activities. Canaccord Genuity may agree or arrange to provide any
prospective strategic partner with, or otherwise assist them in retaining, all or a portion of the financing they may require in connection with a proposed Transaction. In the ordinary course of its business, Canaccord Genuity and its Affiliates may
actively trade the securities (or related derivative securities) of the Company and other companies which may be the subject of the engagement contemplated by this letter for their own account and for the accounts of their customers and may at any
time hold long and short positions in such securities. Notwithstanding the foregoing, Canaccord Genuity (i) shall not represent any counterparty to any Transaction without the prior written consent of the Company, (ii) represents and
warrants that neither it nor any of its Affiliates has now, nor during the Term will it have, any material conflict of interest in connection with the services provided hereunder which the existence of such conflict has not been disclosed in writing
to the Company and waived in writing by the Company, and (iii) will comply with all restrictions under applicable securities laws related to the use of material nonpublic information in the trading of securities. 

15. Securities; Procedural Matters. The Equity Securities issued comprising the Financing shall be offered on terms and conditions, and made pursuant to
one or more purchase, subscription, loan or similar agreements, acceptable to the Company in its sole discretion. In any Financing other than a firm commitment public offering, the Company will have the absolute right to reject any Investor(s) at
any time. Subject to the proviso of the penultimate paragraph of Section 4, the Company will be responsible for taking, and will take, all actions necessary to ensure that the Financing is exempt from applicable federal and state
securities laws. While the Company shall be responsible for the content of any marketing material or other documents used in the placement of securities in the Financing, the Company shall also cause such material and documents to reflect such
content as Canaccord Genuity may reasonably request to comply with applicable securities laws, including any such requests arising out of any legal review of the Financing that Canaccord Genuity’s attorneys may conduct at the request of
Canaccord Genuity. In addition, without the prior written consent of Canaccord Genuity (which consent shall not be unreasonably withheld, conditioned or delayed), such material and other documents may not name or otherwise refer to Canaccord Genuity
or include Canaccord Genuity’s logo. 

 Histogen, Inc. 

November 8, 2019 
  Page
 10
 of 15 
  

 16. Miscellaneous. 

(a) Nothing in this Agreement is intended to obligate or commit Canaccord Genuity to provide any services other than as set forth above. 

(b) This Agreement may be executed in counterparts, each of which shall be deemed an original, but which together shall be considered a single
instrument. Such counterparts may be delivered by one party to the other by facsimile or other electronic transmission, and such counterparts so delivered shall be deemed to have been duly and validly delivered and be legally valid and enforceable
for all purposes. 
 (c) This Agreement constitutes the entire agreement between the parties hereto regarding, and supersedes all prior
agreements and understandings (both written and oral) of the parties hereto with respect to, the subject matter hereof, and cannot be amended or otherwise modified except in writing executed by the parties hereto. 

(d) The provisions hereof shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and Canaccord
Genuity. This Agreement may not be assigned by either party, directly or indirectly (whether by merger, consolidation or otherwise), except (i) with the prior written consent of the other party, or (ii) in connection with a Transaction.
Any purported assignment not in accordance with the foregoing shall be null and void ab initio. 
 (e) Nothing in this Agreement, express or
implied, confers on any third party other than the Indemnified Persons (as defined in Annex A) and each of their respective successors, heirs and permitted assigns, any rights or remedies (directly or indirectly as a third party beneficiary
or otherwise) under or by reason of this Agreement or as a result of the services to be rendered by Canaccord Genuity under this Agreement. 

(f) Canaccord Genuity may refer to the Reverse Merger or Financing, after it is public knowledge, in traditional “tombstone”
announcements or any of its other professional promotional materials, at its sole expense. In connection therewith Canaccord Genuity may use the Company’s corporate logo in such advertising or promotional materials (including electronic
versions thereof). The content of any such announcement, including the use of the Company’s corporate logo, shall not contain any Confidential Information and shall otherwise be subject to the Company’s prior written approval, which
approval shall not be unreasonably withheld. 
 (g) The invalidity or unenforceability of any provision of this Agreement shall not affect
the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect pursuant to the terms hereof. 

(h) This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New York applicable to contracts
negotiated, entered into and to be performed entirely within the State of New York. The parries hereto hereby consent to submit to the jurisdiction of the courts of the State of New York and of the United States District Courts located 

 Histogen, Inc. 

November 8, 2019 
  Page
 11
 of 15 
  

 
in the New York City for any lawsuits, actions or other proceedings arising out of or relating to this Agreement and agree not to commence any such lawsuit, action or other proceeding except in
such courts. CANACCORD GENUITY HEREBY AGREES, AND THE COMPANY HEREBY AGREES ON ITS OWN BEHALF AND, TO THE EXTENT PERMITTED BY APPLICABLE LAW, ON BEHALF OF ITS SECURITY HOLDERS, TO WAIVE ANY RIGHT TO TRIAL BY JURY WITH RESPECT TO ANY CLAIM,
COUNTER-CLAIM OR ACTION ARISING OUT OF THE ENGAGEMENT OR CANACCORD GENUITY’S PERFORMANCE OF SERVICES THAT ARE THE SUBJECT THEREOF. 

(i) All notices (other than legal notices, which shall be provided in accordance with applicable law), approvals, consents and other
communications hereunder shall be in writing, mailed by registered or certified mail, with return receipt requested, delivered by a nationally recognized overnight courier, emailed or hand delivered. Notices and other communications shall be
effective: (i) if given by mail, five days after deposit in the U.S. mails, postage prepaid, addressed to such party at the address set forth below the signature of such party to this Agreement (or such other address as such party may specify in
writing to the other party), (ii) if given by courier or by hand delivery, when delivered to such party, and (iii) if given by email, when a reply (other than an automated reply) is received. 

(j) For purposes of this Agreement, unless the context clearly requires otherwise, (i) the term “electronic transmission” means
electronic mail and any form of communication, not directly involving the physical transmission of paper, that creates a record that may be retained, retrieved and reviewed by a recipient thereof, (ii) the words “include,”
“includes,” and “including” shall be deemed to be followed by the words “without limitation”; (iii) the word “or” is not exclusive; (iv) the words “herein,” “hereof,”
“hereby,” “hereto,” and “hereunder” refer to this Agreement as a whole (including all annexes hereto); (v) references to Sections and Annexes refer to the Sections of, and Annexes attached to, this Agreement;
(vi) references to amounts of money expressed in dollars are references to the lawful currency of the United States; (vii) the singular number includes the plural number and vice versa and reference to any gender includes each other
gender; (viii) a “writing” shall include an electronic transmission, and (ix) the term “termination” when used with respect to a period or agreement shall include the expiration thereof. All references to days in this
Agreement are specifically to calendar days unless otherwise stated. The headings in this Agreement are for reference only and shall not affect the interpretation of this Agreement. 

SIGNATURE PAGE FOLLOWS 

 Histogen, Inc. 

November 8, 2019 
  Page
 12
 of 15 
  

 If you are in agreement with the foregoing, please sign where indicated below and return, whereupon the
Agreement shall become effective as of the date hereof. 
  

			
	Sincerely,
	
	CANACCORD GENUITY LLC
		
	By:	 	 /s/ Eugene Rozelman

		 	Managing Director
	
	ACCEPTED AND AGREED:
	
	HISTOGEN, INC.
		
	By:	 	 /s/ Richard Pascoe

		 	Richard Pascoe
		 	Chairman and Chief Executive Officer

 

 

 Histogen, Inc. 

November 8, 2019 
  Page
 13
 of 15 
  

 ANNEX A 

In the event that Canaccord Genuity LLC (“Canaccord Genuity”) or any of its affiliates and its and their respective shareholders, directors,
officers, agents or employees of Canaccord Genuity, or any other person controlling Canaccord Genuity (collectively, together with Canaccord Genuity, “Indemnified Persons”) becomes involved in any capacity in any action, claim,
suit, investigation or proceeding (any of the foregoing, a “Proceeding”), actual or threatened, brought by or against any Person, including stockholders of Histogen, Inc. (the “Company”), in connection with or as a
result of the engagement contemplated by that certain letter agreement to which this Annex A is attached (the “Agreement”), the Company will reimburse such Indemnified Person for its reasonable legal and other expenses
(including the reasonable costs and expenses incurred in connection with investigating, preparing for and responding to third party subpoenas) incurred in connection therewith as such expenses are incurred; provided, however, that the
Company shall not be liable for such expenses to the extent that it is finally determined by a court or arbitral tribunal in any such Proceeding that any loss, claim damage or liability of Canaccord Genuity or any other Indemnified Person has
resulted from the fraud, bad faith, gross negligence or willful misconduct of Canaccord Genuity or any Indemnified Person, then Canaccord Genuity will promptly repay such portion of reimbursed amounts paid to Canaccord Genuity or any other
Indemnified Person for which the Company is so found to not be liable. The Company will also indemnify and hold harmless each Indemnified Person from and against any losses, claims, damages or liabilities (including actions or proceedings in respect
thereof) (collectively, “Losses”) related to or arising out of the engagement under the Agreement (the “Engagement”), except to the extent any such Losses are finally determined by a court or arbitral tribunal to
have resulted from the fraud, bad faith, gross negligence or willful misconduct of Canaccord Genuity or any Indemnified Person. Unless otherwise noted, all capitalized terms used in this Annex A shall have the respective meanings ascribed
thereto in the Agreement. 
 If such indemnification is for any reason not available or insufficient to hold an Indemnified Person harmless (except by
reason of the fraud, bad faith, gross negligence or willful misconduct of any Indemnified Person), the Company and Canaccord Genuity shall contribute to the Losses involved in such proportion as is appropriate to reflect the relative benefits
received (or anticipated to be received) by the Company, on the one hand, and by Canaccord Genuity, on the other hand, with respect to the Engagement or, if such allocation is determined by a court or arbitral tribunal to be unavailable, in such
proportion as is appropriate to reflect other equitable considerations such as the relative fault of the Company on the one hand and of Canaccord Genuity on the other hand; provided, however, that in no event shall the amounts to be
contributed by Canaccord Genuity exceed the fees actually received by Canaccord Genuity in the Engagement, except to the extent any loss, claim, damage, liability or expense is finally judicially determined by a court of competent jurisdiction to
have resulted from the fraud, bad faith, gross negligence or willful misconduct of any Indemnified Persons. Relative benefits to the Company, on the one hand, and Canaccord Genuity, on the other hand, shall be deemed to be in the same proportion as
(i) the total value paid or proposed to be paid or received or proposed to be received by the Company or its security holders, as the case may be, pursuant to the transaction(s), whether or not consummated, contemplated by the engagement, bears
to (ii) all fees actually received by Canaccord Genuity in the Engagement. 

 Histogen, Inc. 

November 8, 2019 
  Page
 14
 of 15 
  

 Canaccord Genuity shall promptly notify the Company of any actual or threatened Proceedings being asserted
against any Indemnified Person which may give rise to indemnification or contribution hereunder (a “Claim”), provided that the failure to provide such prompt notice shall not affect the Company’s obligations hereunder, unless
and to the extent that the Company is materially prejudiced by such failure. The Company shall have the right to participate in the defense of such Claim and, to the extent the Company shall so desire, to assume the defense thereof, provided,
however, that in the event of the assumption of the defense thereof, such counsel shall be reasonably satisfactory to Canaccord Genuity. Notwithstanding the Company’s election to assume the defense of such Claim, the Indemnified Persons
shall have the right to employ separate counsel designated by Canaccord Genuity and to participate in the defense of such Claim, and the Company shall bear the reasonable fees, costs and expenses of such separate counsel as incurred, if (and only
if) (i) the use of counsel chosen by the Company to represent the Indemnified Persons would, in the reasonable opinion of the Indemnified Persons’ counsel, present the Company’s counsel with a material conflict of interest; (ii) the
actual or potential defendants in, or targets of, such Claim include both the Company and Indemnified Persons, and there are legal defenses available to the Indemnified Persons which are different from or additional to those available to the Company
which result in a material conflict of interest for the Company’s chosen counsel (in which case the Company shall not have the right to assume the defense of such Claim on behalf of the Indemnified Persons); (iii) the Company shall not have
employed counsel reasonably satisfactory to Canaccord Genuity to represent the Indemnified Persons within a reasonable time after notice of the institution of such Claim; or (iv) the Company shall authorize the Indemnified Persons to employ
separate counsel at the Company’s expense. Notwithstanding anything to the contrary herein, the Company shall not be liable for the fees, costs and expenses of more than one separate firm of attorneys (plus one local counsel in each applicable
jurisdiction) in any single Proceeding (or any separate but substantially similar Proceeding or demands arising out of the same general allegations) for all of the Indemnified Persons unless the Company consents in writing or unless an actual,
material conflict of interest requires separate counsel for particular Indemnified Persons. 
 The Company will not, without Canaccord Genuity’s prior
written consent (such consent not to be unreasonably withheld, conditioned or delayed), settle, compromise, consent to the entry of any judgment in or otherwise seek to terminate any threatened or pending Proceeding in respect of which
indemnification may be sought hereunder (whether or not any Indemnified Person is a party thereto) unless such settlement, compromise, consent or termination includes a full, final and unconditional release of each Indemnified Person from any and
all liabilities related to or arising out of such threatened or pending Proceeding. The Company will not permit any such settlement, compromise, consent or termination to include a statement as to, or an admission of, fault, culpability or a failure
to act by or on behalf of an Indemnified Person, without such Indemnified Person’s prior written consent. No Indemnified Person seeking indemnification, reimbursement or contribution hereunder will, without the Company’s prior written
consent (such consent not to be unreasonably withheld, conditioned or delayed), settle, compromise, consent to the entry of any judgment in or otherwise seek to terminate any threatened or pending Proceeding referred to herein. 

 Histogen, Inc. 

November 8, 2019 
  Page
 15
 of 15 
  

 The Company also agrees that neither Canaccord Genuity nor any other Indemnified Person shall have any
liability to the Company or any Person asserting claims on behalf or in right of the Company in connection with or as a result of the Engagement or any matter referred to in the Engagement, except to the extent that any Losses incurred by the
Company are finally determined by a court or arbitral tribunal to have resulted from the fraud, bad faith, gross negligence or willful misconduct of any Indemnified Person. In no event shall Canaccord Genuity or any other Indemnified Person be
responsible for any indirect, special or consequential damages, even if advised of the possibility thereof. 
 In the event that an Indemnified Person is
requested or required to appear as a witness in any action brought by or on behalf of or against the Company relating to the engagement in which such Indemnified Person is not named as a defendant, the Company agrees to promptly reimburse Canaccord
on a monthly basis for all reasonable out-of-pocket expenses incurred by it in connection with such Indemnified Person’s appearing and preparing to appear as such a
witness, including the reasonable fees and disbursements of its legal counsel. 
 The Company’s obligations hereunder shall be in addition to any
rights that any Indemnified Person may have at common law or otherwise. The provisions of this Annex A shall apply to the engagement (including related activities prior to the date hereof) and any modification thereof and shall remain in full
force and effect regardless of the completion or termination of the engagement. 
 END OF ANNEX A

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00304-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00304-of-00352.parquet"}]]